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Safety, tolerability and pharmacokinetics of intravenous ghrelin
for cancer-related anorexia/cachexia: a randomised,
placebo-controlled, double-blind, double-crossover study
Abstract
Twenty-one adult patients were randomized to receive ghrelin on days 1 and 8 and placebo on days 4
and 11, or vice versa, given intravenously over a 60- minute period before lunch: 10 received 2µg/kg
(lower-dose) ghrelin; 11 received 8µg/kg (upper-dose) ghrelin. Active and total ghrelin,
growth-hormone, and IGF-1 levels were monitored at baseline (4-5 days before day 1), during treatment
days, and at end-of-study (day 17/18). Drug-related adverse events (assessed by NCI-CTC-toxicity
criteria and cardiac examination), did not differ between ghrelin and placebo. No grade 3/4 toxicity or
stimulation of tumor growth was observed. The peak increase of growth-hormone, a biological marker
of ghrelin action, was 25ng/ml with lower-dose and 42ng/ml with upperdose ghrelin. Morning fasting
total ghrelin levels were higher (p<0.05) for upperdose patients at end-of-study (3580pg/ml) than at
baseline (990pg/ml). IGF-1 levels did not change. At day 8, 81% of patients preferred ghrelin over
placebo and at the end-of-study, 63%. Nutritional intake and eating-related symptoms, measured to
explore preliminary efficacy, did not differ between ghrelin and placebo. Ghrelin is well tolerated and
safe in patients with advanced cancer. For safety, tolerance, and patients' preference for treatment no
difference was observed between the lower and upper-dose group.
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ABSTRACT 
 
Twenty-one adult patients were randomized to receive ghrelin on days 1 and 8 
and placebo on days 4 and 11, or vice versa, given intravenously over a 60–
minute period before lunch: 10 received 2µg/kg (lower-dose) ghrelin; 11 
received 8µg/kg (upper-dose) ghrelin. Active and total ghrelin, growth-hormone, 
and IGF-1 levels were monitored at baseline (4-5 days before day 1), during 
treatment days, and at end-of-study (day 17/18). Drug-related adverse events 
(assessed by NCI-CTC-toxicity criteria and cardiac examination), did not differ 
between ghrelin and placebo.  No grade 3/4 toxicity or stimulation of tumor 
growth was observed. The peak increase of growth-hormone, a biological 
marker of ghrelin action, was 25ng/ml with lower-dose and 42ng/ml with upper-
dose ghrelin. Morning fasting total ghrelin levels were higher (p<0.05) for upper-
dose patients at end-of-study (3580pg/ml) than at baseline (990pg/ml). IGF-1 
levels did not change.  At day 8, 81% of patients preferred ghrelin over placebo 
and at the end-of-study, 63%.  Nutritional intake and eating-related symptoms, 
measured to explore preliminary efficacy, did not differ between ghrelin and 
placebo. Ghrelin is well tolerated and safe in patients with advanced cancer. For 
safety, tolerance, and patients’ preference for treatment no difference was 
observed between the lower and upper-dose group.  
 
Keywords 
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INTRODUCTION 
Cancer patients often suffer from cancer anorexia/cachexia syndromes 
(CACS) and the consequences—fatigue, weakness, decreased performance 
status, poor tolerance of antineoplastic interventions, and psychosocial distress. 
CACS are characterized by a catabolic state triggered by tumor by-products, 
proinflammatory cytokines, and mediators of the neurohormonal system, 
causing loss of muscle and fat mass, anorexia, gastrointestinal dysmotility and 
early satiety, decreased anabolic drive, and hypermetabolism (Inui 2002). 
There are few pharmacological treatment options for CACS, but is has been 
shown that this patient population with advanced cancer has capacity to 
respond to appetite stimulation therapy (Yavuzsen et al, 2005).  
Ghrelin, an endogenous ligand for the growth-hormone (GH) secretagogue 
receptor, displays dose-dependent GH-releasing activity (Kojima et al, 1999). 
Ghrelin, which is predominantly secreted by gastric endocrine cells, stimulates 
food intake and triggers a positive energy balance through a central mechanism 
involving hypothalamic neuropeptides. In preclinical cachexia models, ghrelin 
has had stimulatory effects on appetite and food intake (Wang et al, 2006; 
Hanada et al, 2003), lean body mass (DeBoer et al, 2007), gastrointestinal 
motility (Date et al, 2002), energy metabolism, and proinflammatory cytokine 
expression (Dixit et al, 2004), and has alleviated cancer chemotherapy-
associated dyspepsia (Liu et al, 2006) and vomiting (Rudd et al, 2006). These 
experimentally induced cancer models provide promising, but not sufficient 
evidence for an effect of ghrelin in human cancer, prompting clinical studies in a 
representative clinical population including long term studies in humans. 
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In human volunteers, intravenous (Nagaya et al, 2001a; Wren et al, 2001; 
Akamizu et al, 2004; Schmid et al, 2005; Levin et al, 2006) or subcutaneous 
(Enomoto et al, 2003; Druce et al, 2006) ghrelin showed safety and tolerability 
at dosages up to 10mcg/kg—sufficient to promote orexigenic, prokinetic, and 
GH-releasing effects; in those studies, a sensation of warmth, sleepiness, bowel 
movements, and hunger were reported. Comparable results with intravenous 
ghrelin (single-dose bolus, daily for 3 weeks, or iv infusion) were reported in 
patients with chronic heart failure (Nagaya et al, 2001b; Nagaya et al, 2004), 
COPD (Nagaya et al, 2005), or diabetic gastroparesis (Murray et al, 2005).21 
In melanoma-bearing nude mice, ghrelin plasma concentration increased 
with cachexia progression (Hanada et al, 2004). In cancer patients with 
cachexia (various cancers, n=21 [Garcia et al, 2005]; breast and colorectal 
cancer, n=18 [Wolf et al, 2006]; lung cancer, n=21 [Shimizu et al, 2003]), ghrelin 
morning fasting levels were 1.3-fold to 1.5-fold higher than in those without 
cachexia and healthy controls. In contrast, ghrelin levels were normal in 
subgroups of patients in one study (39%) (Wolf et al, 2006) and all patients in 
another study (gastric and colorectal cancer, n=58)(Huang Q et al, 2007). 
Lower ghrelin values in patients with colorectal cancer (n=29) than in healthy 
controls (n=50) were also reported (D’Onghia et al, 2007). Preliminary findings 
suggest that pharmacological doses of ghrelin alleviate cancer cachexia. 
Tumor-bearing mice showed improved food intake and body composition only 
at a high intraperitoneal dose (40mcg/day) of ghrelin (Wang et al, 2006). In one 
pilot study, seven cancer patients had 31% higher energy intake with 
intravenous ghrelin than with placebo (5pmol/kg/min for 180 minutes, equals 3 
µg/kg), with no adverse effects (Neary et al, 2004). 
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This trial was conducted to assess safety, tolerability, and pharmacokinetics 
in a 2-week trial of ghrelin infusion given intravenously, at one of two dose 
levels, once weekly, 1 hour before lunch, to patients with far-advanced, 
incurable cancer and involuntary loss of weight and appetite. 
 
MATERIALS AND METHODS 
This single-center, randomized, double-blind, placebo-controlled, two-arm, 
double-crossover study adhered to Good Clinical Practice (GCP) and the 
Declaration of Helsinki and was approved by the local Ethical Review Board 
and Health Authorities. 
 
Participants 
Physicians at the Kantonsspital in St. Gallen, Switzerland, recruited adult 
patients with advanced incurable cancer who had loss of appetite (≥3 visual 
analogue scale [VAS; 0=best, 10=worst]) and, a weight loss of ≥2% within 2 or 
≥5% within 6 months before the study not related to recent surgery.  
Eligible patients gave written informed consent to participate, were able to 
eat without assistance, did not receive enteral or parenteral nutrition, and had 
no significant causes of secondary anorexia (defined as no severe symptoms or 
complications of the gastrointestinal tract impeding oral food intake)(Omlin and 
Strasser, 2007), as ensured by pre-baseline palliative oncology assessments. 
Patients were expected not to require new systemic antineoplastic treatment for 
the total study period of 3 weeks; those with unchanged continuous or weekly 
treatment for at least 2 months were eligible. Concomitant medication was to 
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remain unchanged for at least 1 week before baseline. One patient having 
octreotide treatment was removed from analysis. 
 
Intervention 
In a randomized, double-blind, placebo-controlled, double-crossover trial, 4–
5 days after baseline, patients received ghrelin on days 1 and 8 and placebo on 
days 4 and 11 or vice versa; end-of-study was day 17/18 (Fig 1). 
On treatment days, patients ingested only water from midnight to breakfast.  
In the outpatient clinic, safety laboratory values and fasting hormone blood 
samples (including testosterone in male patients) were drawn at 8am; venous 
access was maintained for pharmacokinetics. Patients received a standardized 
breakfast (120g bread, 20g butter, 60g jam, 2dl coffee with milk). At 10am, a 
second intravenous line was inserted in the other arm for treatment given from 
10:30–11:30am. Immediately after the end of the infusion, patients walked in 
approx. 5 minutes the 90 meters to the restaurant, where they received priority 
serving starting the meal within 5 minutes. A hospital volunteer accompanied 
the patients and documented the conditions (i.e., quality of service, quiet 
atmosphere) at lunch. Following evaluations performed after lunch, all patients, 
except one inpatient, returned home.  
Ghrelin of Good Manufacturing Practice quality was purchased from Clinalfa 
(Merck Biosciences, Switzerland) as vials of 88mcg, stored at –20°C, and 
dissolved in 250ml normal saline by the hospital pharmacy immediately before 
application. The treatment was titrated up within the first 10 minutes (20% 
increase each 2 minutes) and maintained for the next 50 minutes. The lower-
dose group (LD) received 10pmol/kg/min (equals 0.0336mcg/kg/min, 
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approximately 2mcg/kg). The dose was based on the reported maximal GH-
stimulation in human volunteers (Wren et al, 2001) and multiplied by 2 to 
account for suspected ghrelin resistance (Shimizu et al, 2003). After observing 
treatment tolerance in the LD patients, we administered the upper-dose group 
(UD) 40pmol/kg/min (approximately 8mcg/kg). Normal saline was used as 
placebo. 
 
Objectives 
We tested the safety and tolerability of two dose levels of intravenous ghrelin 
in patients with far-advanced cancer based on toxicity, tumor measurements, 
and patients’ perceived tolerance. We also assessed pharmacokinetics.  
 
Outcome measures  
Patients were assessed at each visit by using the NCI-CTC toxicity criteria 
Version 3.0, including standard blood examinations (hematology, chemistry 
panels), and cardiology evaluations, including echocardiography at baseline 
and end-of-study. During the treatment phase, research personnel regularly 
contacted patients at home during the daytime to check for their safety. Before 
each infusion for each patient, the responsible investigator reviewed treatment 
logs for the preceding infusions and the results of the morning laboratory 
examinations. On study day 7 and at end-of-study, patients were asked about 
their perception of their tolerance and preference of the day 1 (and 7) versus 
the day 4 (and 11) treatments. Radiological measurements were made within 
2 weeks before the first infusion and within 2 weeks after the last infusion by 
CT-scans, expect for two patients with liver metastasis who had once a 
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ultrasound (#11) or an MRI (#18), and for one patient monitored only by 
ultrasound (#11) or once at study end (#4), and one patient who had a prior MRI 
liver metastasis were monitored by ultrasound, one patient had ultrasound of 
liver. An independent radiologist reviewed all films made before baseline, at 
baseline, and at end-of-study to judge tumor size and dynamics. 
Patients’ nutritional intake was monitored daily. At baseline, dieticians 
assessed patients’ food preferences, reviewed the procedures and meals for 
the next 2 weeks, and distributed a food scale and standard protocols for 
prospective “third-person” (family members of patients) assessments (Bruera et 
al, 1986). A trained volunteer accompanied patients at lunch in a designated 
quiet section of the hospital restaurant. Meals were photographed and kitchen 
personnel documented the weight of each meal component before and after 
each patient ate.  
To detect acute symptom effects of treatment, VAS assessments (0=best, 
10=worst) of appetite, hunger, anxiety, early satiety, nausea, and fatigue were 
measured before, during, and after infusion. Immediately after lunch on 
treatment days, VAS assessments of the pleasantness of the meal, perceived 
appetite, and perception of amount of food intake were obtained.  
For ghrelin assays, 5ml blood were collected in a precooled EDTA 
vacutainer tube containing aprotinin (33 kIU), placed immediately on ice, and 
centrifuged (4°C, 3000G, 5 minutes). For each milliliter of plasma, 10ul PMSF-
Isopropanol, 50ul 1N-HCL, and 50ul aprotinin were added, and aliquots were 
stored at –80°C until batch analysis. Serum was collected and cooled for GH, 
insulin-like growth factor 1 (IGF-1), Interleukin-6 (IL-6) and leptin analysis. 
Testosterone radioimmunoassays (Diagnostic Products Corporation; Bühlmann, 
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Salzburg, Austria) were performed from serum sent for routine safety labs. The 
radioimmunoassay kits used for total and active ghrelin were from Linco 
Research (St. Charles, Missouri); for GH (active GH IRMA immunoradiometric 
assay) from Diagnostic Systems Laboratory (Webster, Texas); for IGF-1 
(human, bovine) from Peninsula Laboratories (San Carlos, California), for IL-6 
(Quantikine human ELISA) from R&D Systems (Minneapolis, MN), and for leptin 
(human RIA) from Millipore (Billerica, MA).   
Autonomic dysfunction was assessed as described previously (Strasser et 
al, 2006). Standard deviation of beat-to-beat intervals (SDNN) was analyzed at 
baseline and end-of-study for 20 minutes in both the LD and UD; and in the UD, 
in addition, 30 minutes before infusion until after lunch on treatment days. 
 
Sample size 
Safety and tolerability was assessed based on a sample size of 10 patients 
per dose level.  
 
Treatment assignment, randomization, and blinding  
Patients were randomized by independent personnel at the hospital 
pharmacy, where the random allocation sequence produced (switches after 1 to 
maximal 3 patients) was assigned and sealed envelopes for each patient were 
distributed. A master randomization list was kept in a locked container at the 
pharmacy. Copies of the documents in each sealed envelope were stored in a 
locked container accessible to clinicians for emergencies, as required by GCP 
standards.  
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Less than 30 minutes before each infusion, the pharmacy produced identical 
bags containing indistinguishable liquids of 250ml normal saline with or without 
ghrelin.  
The database was closed after completion of the study and rating of all 
adverse events. Thereafter, an independent senior physician who had 
controlled the randomization procedure, the master randomization list, and the 
broken envelopes revealed the treatment assignments. 
 
Statistical analyses 
All analyses were performed with SPSS (Version 11.5).  Descriptive 
statistics was used for demographic and baseline variables, frequencies of 
adverse events and tumor measurements. For exploratory analyses of patients’ 
preference of treatment, we used the exact binominal test. For 
pharmacokinetics (GH, Ghrelin), glucose values, IGF-1 levels, nutritional intake 
and SDNN a comparison was made between changes from baseline for each 
individual subject between the two interventions (sum of two ghrelin periods 
versus sum of two placebo periods). For between patient comparison of peak 
GH (median), the Wilcoxon (no-signed) rank sum test (Mann-Whitney) was used; and 
for within patient comparisons (ghrelin morning fasting levels 3 days after the 
prior ghrelin infusion, glucose, IGF-1, nutritional intake and SDNN) values the 
Wilcoxon signed rank test. 
 
RESULTS 
Flow (Fig 1) and demographics (Table 1) for the 20 patients studied were 
recorded. Oral intake at the fixed breakfast at treatment days was 296 kcal (SD 
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80) in LD and 276kcal (118) in UD; one patient in LD and 5 in UD eat less than 
250kcal. Most patients (17 of 20) had ongoing inflammation (C-reactive protein 
[CRP] >10mg/ml)(Fearon et al, 2006). Creatinine was 83µmol/l (mean, SD 31) 
in LD and 73µmol/l (17) in UD, one patient each in LD and UP had a value 
above normal (<105µmol/l). No patient had malignant gastroparesis. Two 
patients stopped study treatment early in the second week because of 
malignant bowel obstruction and blood-culture positive infection, respectively.  
Treatment of one patient was unblinded during the study because of 
apoplectiform deafness. 
Concomitant preexisting medications included laxatives (76%), opioids 
(67%), propulsive drugs (67%), antacids (62%), vitamins (57%), and many 
others. Three patients (upper dose only) were on unchanged treatment for >1 
week with megestrol acetate (160mg twice daily) and three different patients on 
intramuscular testosterone, and one patient each received fish oil (500mg twice 
daily) or dexamethasone (8mg/day). Six patients (29%) received anticancer 
agents before and during the study (three gemcitabine; one each irinotecan, 
vinblastine, or bevacizumab). One patient was started on dexamethasone (4mg 
twice daily) for liver capsule pain on day 14. 
Of 205 adverse events, 49 possibly and 9 probably were related to an agent 
studied—placebo as well as ghrelin (Table 2). They included abnormal liver 
tests or low potassium (three patients on ghrelin, four on placebo); increased 
serum amylase, creatinine, and D-Dimer (seven on placebo); and increased 
CRP (two on ghrelin). Blinded clinicians rated the other adverse events as 
unrelated or probably unrelated to treatment. Those were: cardiac arrhythmia 
during LD ghrelin infusion; constipation or infection with UD ghrelin; sinus 
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tachycardia, pulmonary rales, increased stool frequency, or back pain with LD 
placebo; and blurred vision with UD placebo. Body temperature and oxygen 
saturation remained unchanged during and after the infusion of ghrelin and 
placebo in both dosage groups. Of 13 serious adverse events, one—transient 
apoplectiform deafness on day 13—was judged as probably related to 
treatment on day 11 (placebo).  
The mean scores for tolerability of the study medication immediately after 
infusion and after lunch did not differ between ghrelin and placebo or between 
LD and UD. More patients preferred ghrelin over placebo (Table 3) at day 7 and 
at end-of-study, with no evidence of patients’ awareness of their treatment 
assignment. 
During the study period, two patients experienced progressive disease (PD). 
Before enrolment, one had had stable disease (SD) and one PD. Of 16 patients 
with SD during the study period, 10 had PD, five had SD, and one had partial 
response before enrolment. Of two patients who stopped study treatment early, 
one had SD and one had PD at enrolment. The mean time interval between 
tumor assessments pre-baseline and at baseline was 79 days in LD and 29 
days in UD, and between assessments at baseline and after the study was 34 
and 25 days, respectively.  
For total ghrelin, in the upper dose group elevated morning fasting levels 3 
days after the prior ghrelin infusion were observed compared to after placebo 
(p<0.001), as confirmed by an independent, blinded laboratory (Fig 2). 
The mean differences of the peak GH levels (of week 1 and week 2) 
compared to baseline were higher in UD (50ng/ml [SD 20]) than LD (28ng/ml 
[6]) (p=0.004). 
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In one patient (UD) having had gastrectomy 6 months before baseline, no 
substantial differences in baseline values nor peak levels of active or total 
ghrelin or GH were detected.  
IGF-1 did not increase at day 17/18 as compared to study start in any 
patient examined (maximal increase from baseline was 170%); mean IGF-1 
was 1359pg/100ul (±994) in LD (n=7) and 1096pg/100ul (±495) in UD (n=9), 
and mean change from baseline -2624pg/100ul (±2888) and -624pg/100ul 
(±962) (p=0.055). 
During treatment days, blood glucose values compared to baseline after 
infusions were higher when patients received ghrelin than when receiving 
placebo in LD only after lunch (3.6 mmol/l versus  2.5 mmol/l [p=0.005]) but not 
after infusion (1.5 mmol/l versus  1.3 mmol/l, p=0.16), in UD both after lunch  
(2.4 mmol/l versus  1.3 mmol/l [p=0.01]) and after infusion  (0.8 mmol/l versus  
0.2 mmol/l [p=0.044]). 
Plasma levels of interleukin-6 did not change throughout the treatment 
period (results not shown). 
There were no significant differences in nutritional intake or symptoms 
compared to baseline when patients received ghrelin or placebo. Nutritional-
intake-at-lunch compared to baseline was in LD -105kcal with ghrelin and -
17kcal with placebo, in UD 251kcal and 230kcal, respectively; nutritional-intake-
lunch-and-rest-of-the-day was (LD) 145kcal and 228kcal, and (UD) 244kcal and 
156kcal, respectively (all p=ns). In UD patients not receiving concurrent 
chemotherapy (n=8), a trend toward increased differences compared to 
baseline for nutritional-intake-lunch-and-rest-of-the-day (ghrelin: 448kcal; 
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placebo: 128kcal; p=0.093) but not nutritional-intake-at-lunch (ghrelin: 330kcal; 
placebo: 200kcal; p=ns) was observed.  
Mean SDNN was 57±28msec at baseline and 73±57msec at end-of-study in 
18 evaluable patients (p=ns); in UD (n=9), for ghrelin 84±40msec and for 
placebo 78±35msec in week 1 (p=ns), and in week 2, 75±35msec and 
80±27msec (p=ns), respectively.  
 
DISCUSSION 
This is, to our knowledge, the first trial investigating two doses of ghrelin in 
patients with advanced cancer and anorexia/cachexia. Intravenous ghrelin 
infusion for 60 minutes at 2mcg/kg or 8mcg/kg body weight is well tolerated and 
safe in these patients, who represent a “real world” population of cancer 
patients with anorexia/cachexia. 
At present, no dose-limiting toxicity has been reported for ghrelin in animals 
or humans. The dosage used was based on the reported maximal GH 
stimulation in human volunteers (Wren et al, 2001), and prior trials using up to 
10mcg/kg in healthy volunteers and 6mcg/kg in patients (Nagaya et al, 2001b). 
Our data suggest a dose relationship with GH-stimulation. In cachectic tumor-
bearing mice (MCG101), higher ghrelin doses were required to increase food 
intake and body weight than in control mice (Wang et al, 2006). Other 
interventional CACS studies did not compare ghrelin doses (Hanada et al, 
2003; Neary et al, 2004; DeBoer et al, 2007). 
Morning fasting levels of ghrelin in patients (Shimizu et al, 2003; Garcia et al, 
2005; Wolf et al, 2006; Huang et al, 2007) or animals (Hanada et al, 2004; Liu 
et al, 2006) with CACS are still poorly understood. In animals both higher 
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(Hanada et al, 2004) and lower (Liu et al, 2006) ghrelin levels than controls are 
reported. Several studies showed higher ghrelin levels (Shimizu et al, 2003; 
Garcia et al, 2005) or higher levels only in subgroups (61% of 18 breast and 
colorectal cancer patients) (Wolf et al, 2006) in patients with CACS as 
compared to non-cachetic cancer patients or healthy controls; however, normal 
(Huang et al, 2007) ghrelin levels were reported, as well. The differences of 
fasting levels of ghrelin in cancer patients may be explained by differences in 
BMIs, we had in LD 20.7kg/m2 and 20.6kg/m2 in UD, others 18.5kg/m2 (Shimizu 
et al, 2003). It remains unclear whether ghrelin plasma levels are increased in 
cancer patients, and whether high plasma levels of ghrelin will induce 
resistance to ghrelin. It remains to be clearly shown, whether the response to 
peripheral ghrelin differs depending of the prevailing ghrelin level.  
In transgenic mice overexpressing ghrelin, acute stimulation of food intake of 
exogenous ghrelin was not diminished (Wei et al, 2006). In patients with 
anorexia nervosa, in whom chronic hyperghrelinemia presents with 2-fold to 
3-fold increased levels (Broglio et al, 2004), intravenous ghrelin (1mcg/kg per 
hour for 5 hours [5pmol/kg/min x 300min; Miljic et al, 2006] or 1mcg/kg [Broglio 
et al, 2004]) caused much lower GH and glucose increases than in healthy 
volunteers, and caused no appetite stimulation but increased sleepiness. In two 
patients having ghrelin producing tumors in gastro-entero-pancreatic system 
(Corbetta et al, 2003; Tsolakis et al, 2004) BMI remained high and appetite 
good despite failure to respond to anticancer treatment. 
In our study we observed no major unexpected tumor-growth dynamics, but the 
study design with short intervals of the tumor measurements impedes firm 
conclusions. As ghrelin is also a potent GH secretagogue, there are concerns 
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about GH-mediated stimulation of tumor growth, especially regarding treatment 
of cancer patients. Several cell lines express the ghrelin-receptor (Yeh et al, 
2005; Ekeblad et al, 2006) and secrete ghrelin (Yeh et al, 2005). In vitro studies 
suggest that ghrelin may enhance proliferation of prostate (Yeh et al, 2005) and 
pancreatic (Duxbury et al, 2003) cancer cells, but not of a lung cancer cell line, 
where it induced dose-dependent inhibition of cell proliferation and increased 
apoptosis (Cassoni et al, 2006). Some tumors from archival samples express 
ghrelin (Jeffery et al, 2005), whereas others do not (Cassoni et al, 2006; 
Mottershead et al, 2007) Tumor incidence is not increased in patients with 
anorexia nervosa (Mellemkjaer et al, 2001) despite elevated ghrelin levels. The 
hepatic GH effector IGF-1 levels are not correspondingly increased in 
conditions with high endogenous plasma ghrelin levels such as ghrelin-
producing tumors (Corbetta et al, 2003; Tsolakis et al, 2004). Furthermore 
administration of ghrelin does not significantly affect the IGF-1 level in healthy 
volunteers (Enomoto et al, 2003), patients with cardiovascular (Nagaya et al, 
2004) or pulmonary diseases (Nagaya et al, 2005), tumor-bearing animals 
(DeBoer et al, 2007), or our patients with CACS. In contrast studies using 
synthetic oral ghrelin-mimetics have shown a significant effect on the IGF-1 
level in volunteers and frail elderly (Smith, 2005) or patients with cancer 
cachexia (Garcia et al, 2007).  
Higher morning fasting total ghrelin levels 3 days after intravenous ghrelin 
administration suggest a carryover effect. As the half-life of ghrelin is short—
approximately 15 minutes—a systematic mistake in the analysis was thought 
likely, but an independent, blinded laboratory confirmed our results. Ghrelin 
levels were normal before infusion at 10:30am. Renal function was not 
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impaired. These unexpected findings of total, but not active ghrelin, remain 
unexplained at present, but may indeed be without any physiological 
significance. 
Our study of patients with far-advanced cancer was not designed to detect 
effects on nutritional intake, eating-associated symptoms, or lean-body mass.  
We found no major differences for these efficacy parameters between ghrelin 
and placebo in preliminary analyses. Our finding contrasts with data observed in 
animal models (Hanada et al, 2003; Wang et al, 2006; DeBoer et al, 2007). Our 
methodology with treatment of secondary anorexia, nutritionist-monitored lunch 
meals, full placebo control of all outcomes, and standardized procedures and 
time schedules makes systemic errors unlikely.  
In contrast to one recent small series of patients with mainly (5/7) breast 
cancer (Neary et al, 2004), our patients had tumors typically leading to CACS. A 
high intrapatient variability of symptoms and nutritional intake is reported in 
patients with advanced, incurable cancer (Stromgren et al, 2006). Baseline food 
intake (Gilg and Lutz, 2006) and dietary patterns with high protein or liquid 
intake (Blom et al, 2006) may influence ghrelin regulation. Drugs for symptom 
control (for example, haloperidol [Jaszberenyi et al, 2006], 5-HT-3 antagonist 
[Depoortere et al, 2006]) may interact with ghrelin metabolism. Patients often 
have enhanced levels of proinflammatory cytokines and stress, which are 
reported to increase preprandial activation of ghrelin secretion (Kristenssson et 
al, 2006) by activation of sympathetic nerves but not by epinephrine (Mundinger 
et al, 2006). Alterations in testosterone levels may influence ghrelin regulation, 
as testosterone treatment in prepubertal boys decreased ghrelin values 
 
 
 18
(Lebenthal et al, 2006). Patients may have remaining side-effects of prior 
chemotherapy mediating CACS (Hutton et al, 2007). 
Ghrelin may prolong the premature gastric phase III of migrating motor 
complex tone in the proximal stomach (Tack et al, 2006), leading to enhanced 
gastrointestinal motility without (Tack et al, 2006) and with (Liu et al, 2006) 
increased food intake, but some studies show no stimulatory effect of ghrelin on 
motility (Depoortere et al, 2006; Ohno et al, 2006). Patients with advanced 
cancer often have autonomic dysfunction (Strasser et al, 2006), as did 83% of 
our patients. We found no differences in autonomic function during or after two 
single infusions of ghrelin.  
Some of our patients seem to prefer ghrelin over placebo, this may 
associated with the effect of peripheral ghrelin targeting the mesolimbic reward 
circuitry (Abizaid et al, 2006). Limitations of this study design include the lack of 
chronic efficacy data beyond two weekly infusions; namely, body composition 
(lean body mass, fat mass [Theander-Carrillo et al, 2006]), objective 
subconscious locomotive motor and physical activity (Jaszberenyi et al, 2006), 
energy expenditure measurements (Lejeune et al, 2006), and gastrointestinal 
motility (Binn et al, 2006; Blom et al, 2006). Our results on dose responsiveness 
may be influenced by unbalanced groups: UD patients had more metastases, 
greater weight loss, lower dietary intake, more early satiety, and were closer to 
death. However, given the double-crossover design, no effect on outcomes is 
expected from unequal (4 versus 7) randomisation in the UD-group. 
Our patients studied represent a very diverse population, since this trial was 
conducted with more or less unselected patients with CACS having mostly far 
advanced cancer, as the median survival documents, and various tumor types. 
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Our main aim was to explore safety and tolerability of intravenous ghrelin in 
such a clinical situation, interpretation of (negative) efficacy data requires 
considerable caution. In the two patients with stomach and oesophageal 
cancer, the clinical efficacy of ghrelin may be limited, since ghrelin induced in 
patients having had vagotomy only an increase in GH secretion, but not in 
energy intake (Le Roux et al, 2006). Given the foreseen clinical application, 
namely a relatively short interval between intervention and meal, but not at the 
same time (difficult for patients to have continuous infusions during meals, or to 
inject subcutaneously “real time” during meals) we chose to offer lunch 
immediately after, but not during, the ghrelin infusion, this time difference may 
explain the lack of difference in energy intake observed between ghrelin and 
saline.The safety and tolerability data support further exploration of the 
therapeutic potential of natural ghrelin, namely escalation of dose (Wang et al, 
2006) and frequency and chronic administration. The patient population may 
stratified for baseline ghrelin levels (Wolf et al, 2004; Garcia et al, 2005), other 
factors need to be controlled for, namely genetic alterations of the ghrelin gene 
(Holst and Schwartz, 2006), cytokine levels (Dixit et al, 2005), stress level 
(Kristenssson et al, 2006) hypogonadism (Strasser et al, 2006), patients eating 
preferences (Blom et al, 2006), baseline food intake (Gilg and Lutz, 2006) and 
gastric emptying (Binn et al, 2006). These strategies may counteract the series 
of  many negative cachexia phase III trials (EPA, cannabinoids) or single not 
confirmed studies (ATP, thalidomide), treating uniformly all patients having loss 
of weight and appetite, despite promising patho-physiological concepts. 
In conclusion, ghrelin administered intravenously as one therapeutic dose 
and repeated once after 1 week was safe and well tolerated by both LD and UD 
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patients with far-advanced cancer and anorexia/cachexia. Several patients 
preferred ghrelin over placebo, despite a lack of major differences in food intake 
or symptoms. The stimulation of GH, reflecting biological activity, was dose 
dependent. Anorexia/cachexia remains a burdensome clinical problem with few 
treatment options. Further research with ghrelin will explore dose escalations, 
route and schedule modifications, and mechanisms of ghrelin resistance. 
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Figure Legends 
 
Figure 1.   Flow of patients in a randomized, placebo-controlled, double-blind, 
double-crossover trial of intravenous ghrelin for cancer-related 
anorexia/cachexia.  
 
Figure 2.  Pharmacokinetics of active and total ghrelin of the upper dose 
patients 
 
 Legend: BL: Baseline 
  I-V blood samples week 1  
- I: morning fasting 
- II: immediately before ghrelin infusion [10:30] 
- III: during ghrelin infusion 
- IV: after ghrelin infusion [11:30] 
- V: after lunch [12:30]) 
Ia-Va blood samples week 2 
EOS: end of study 
P<0.001 for differences of morning fasting level of total ghrelin 3 
days after ghrelin or placebo  
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Table 1.  Demographics of 21 Patients with Cancer-Related Anorexia/Cachexia 
 
 Lower-Dose Group 
(n=9) 
Upper-Dose Group 
(n=11) 
 Age (years) 
 Median (min, max) 
 
66 (45, 73) 
 
70 (45, 80) 
Gender   
Female / Male 1 / 8 2 / 9 
Diagnosis   
Pancreatic cancer  1 3 
Mesothelioma 2 0 
Prostate cancer 1 2 
Colorectal cancer 3 1 
Stomach/esophageal cancer 0 2 
NSCLC 1 2 
Urogenital cancer 1 0 
Cholangiocarcinoma 0 1 
Metastasis (all pts >=1; none CNS)   
Liver 4 6 
Lung 4 2 
Bone 3 6 
Peritoneal 2 4 
Lymph node 1 8 
Survival time (days)   
Median (min, max) 233 (14, 436) 67 (16, 386) 
Prior Chemotherapy (number of regimens)  
0 3 3 
1 1 4 
2 3 2 
3-5 2 2 
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Prior Radiation therapy 3 5 
Prior Hormonal Therapy 1 2 
Weight (kg)   
Median (min, max) 59 (54, 95) 54 (44, 77) 
Body Mass Index (kg/m2)   
Median (min, max) 21.7 (15.7, 30) 20.6 (17.3, 30.4) 
Weight loss last 2 months (%)   
Median (min, max) 3.6 (2.2, 15.1) 6.0 (3.6, 11.5)* 
Nutritional intake at lunch (kcal)   
 Median (min, max) 650 (144, 1133) 304 (179, 700) 
Nutritional intake, whole day (kcal)   
 Median (min, max) 1237 (222, 1864) 889 (179, 1876) 
Appetite  (0=best, 10=worst)   
Median (min, max) 60 (7, 80) 71 (14, 89) 
Early satiety (0=no, 10=worst)   
Median (min, max) 25 (2, 79) 52 (10, 95) 
 Heart rate before 1st infusion (BPM)   
Median (min, max) 90 (50, 103) 83 (54, 120) 
C-reactive protein (mg/ml) 
Median (min, max) 
 
25 (2, 178) 
 
24 (3, 145) 
Free testosterone (pmol/l)**   
Median (min, max) 22.4 (2.3, 170) 12.6 (<0.5, 25) 
Ghrelin, total (pg/ml)   
Median (min, max) 1041 (317, 1416) 1015 (533, 2598) 
Ghrelin, active (pg/ml)   
Median (min, max) 121 (24, 322) 102 (11, 250) 
Leptin (ng/ml)   
Median (min, max) 0.8 (0.4, 6.4) 1.9 (0.3, 7.4) 
Growth hormone (pg/ml)   
Median (min, max) 1.2 (0.3, 4.9) 1 (0.3, 3.8) 
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IGF-1 (pg/100ul)*** 
Median (min, max) 
 
3968 (808, 9143) 
 
1820 (1121, 3675) 
Plasma glucose (mmol/l) 
Median (min, max) 
 
4.8 (4.1, 7.5) 
 
5.6 (4.4, 7.9) 
Prior Major Gastrointestinal Surgery   
Gastrectomy 0 1 
Whipple procedure 0 1 
* Two patients had missing data on weight loss 2 months before study entry, but had weight 
loss 6 months before study entry of 8% and 11.6%, respectively. 
   NSCLC = non-small cell lung cancer; CNS = central nervous system; BPM = beats per 
minute; IGF-1 = insulin-like growth factor 1. 
** Testosterone levels are reported only for men (LD n=8, UD n=9) 
*** IGF-1 levels are reported for LD n=8 and UD n=11 
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Table 2.  Adverse Events of Treatment with Intravenous Ghrelin in 21 Patients 
with Cancer-Related Anorexia/Cachexia 
 
Lower-Dose Group 
(n=9) 
Upper-Dose Group 
(n=11) 
Adverse Events Related to Study Drug 
(probable or possible, all NCI-CTC grade 1 or 2) 
Ghrelin Placebo Ghrelin Placebo 
During infusion on treatment days     
 Increased bowel activity1 3 5 5 3 
 Abdominal pain   3  
 Dry mouth   3 1 
 Worsening of pre-existing neuropathy    1  
 Dizziness    1 
 Shortness of breath (overeaten, aspiration)2 1 1   
 Chest pain     
 Nausea  1   
 Increased stool frequency  1   
 Sweating 2    
 Asthenia   1  
Between infusion days     
 Abdominal pain   2  
 Apoplectiform deafness  1   
 Diarrhea   1 1 
 Nausea   1  
 Vomiting3 1 2   
 Constipation  1   
1  In 5 patients both on ghrelin and placebo 
2,3  In 1 patient both on ghrelin and placebo 
 NCI-CTC = Common toxicity criteria (CTC) established by the National Cancer Institute (NCI) 
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Table 3.  Patients’ Preference of Treatment between Placebo and Intravenous Ghrelin 
 
 Day 7 End-of-Study 
 Lower dose  
(n=9) 
Upper dose  
(n=11) 
Lower dose  
(n=9) 
Upper dose  
(n=9) 
 G-P 1 P-G 1 G-P 1 P-G 1 G-P-G-P 1 P-G-P-G 1 G-P-G-P 1 P-G-P-G 1
Treatment Preference (VAS), median (min, max) 2 42 (3,66) 80 (49,100) 45 (2,96) 77 (54,100) 20 (10,99)) 54 (5,100) 69 (56,94) 83 (56,100)
Preference for Ghrelin (cutoff VAS 50),3 number (%) 7 (78%)4 9 (82%)5 6 (67%)6 6 (60%)6 
 
1 Treatment sequence (G = Ghrelin, P = Placebo) 
2 Visual Analogue Scale (VAS: 0-100), low numbers indicate that the patient prefers 1st (day 7) and 3rd (end-of-study) treatment, high numbers 2nd and 4th 
treatment, respectively. 
3 VAS treatment preference score < 50 in patients receiving the Ghrelin-Placebo-Ghrelin-Placebo order, 100-VAS score > 50 in patients receiving the Placebo-
Ghrelin-Placebo-Ghrelin order 
4-6 Exact binominal 2-sided tests: 4: p = ns, 5: p = 0.065, 6: p = ns 
 
 
Comment [MSOffice1]: Cont
rolled after deletion of UPN1 
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N = 10 
BASELINE AFTER INFORMED CONSENT 
DAY 1 TREATMENT 
DAY 4 TREATMENT 
DAY 8 TREATMENT 
DAY 11 TREATMENT 
END OF STUDY:  
DAY 17/18 
N = 11 
PATIENTS RANDOMIZED 
BASELINE: 4-5 
DAYS BEFORE DAY 1 
N = 9 
END OF STUDY EXAMINATION 
N = 9 
END OF STUDY EXAMINATION 
TREATMENT A 
N = 4 
GHRELIN 
N = 4 
PLACEBO 
N = 4 
GHRELIN 
N = 4 
PLACEBO 
TREATMENT B
N = 5 
PLACEBO 
N = 5 
GHRELIN 
N = 5 
PLACEBO 
N = 5 
GHRELIN 
N = 12 
BASELINE AFTER INFORMED CONSENT 
TREATMENT A
N = 4 
GHRELIN 
N = 4 
PLACEBO 
N = 4 
GHRELIN 
N = 3 
PLACEBO 
TREATMENT B
N = 7 
PLACEBO 
N = 7 
GHRELIN 
N = 7 
PLACEBO 
N = 6 
GHRELIN 
N = 10 
PATIENTS RANDOMIZED 
N = 18 
PATIENTS SCREENED 
N = 20 
PATIENTS SCREENED 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low-dose Upper-dose 
Drop out 
Infection 
day 8 
Drop out 
Ileus 
day 10 
Figure 1 
Drop out 
Treated with 
octreotide 
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Figure 2 
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